Deutsche Bank
ATXI

Deutsche Bank’s Avenue Therapeutics, Inc. Common Stock ATXI Stock Holding History

Deutsche Bank’s Portfolio ATXI Stock Details ATXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-4
Closed -$26K – 4840
2021
Q1 		$26K Hold
4
– – ﹤0.01% 4354
2020
Q4 		$28K Buy
4
+1
+33% +$5.24K ﹤0.01% 4214
2020
Q3 		$37K Hold
3
– – ﹤0.01% 3998
2020
Q2 		$33K Buy
+3
New +$33.8K ﹤0.01% 3968
2020
Q1 		– Hold
0
– – – 4914
2019
Q4 		– Sell
-1
Closed -$6.99K – 5172
2019
Q3 		$4K Sell
1
-5
-83% -$34K ﹤0.01% 4708
2019
Q2 		$42K Sell
6
-4
-40% -$23.2K ﹤0.01% 4583
2019
Q1 		$51K Buy
+10
New +$63.8K ﹤0.01% 4552

Other funds holding ATXI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EL
EMFO LLC Weston, Florida $112M AUM 18.79% 1-Year Est. Return
ASN
Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Deutsche Bank's ATXI Position: Q2 2021 in Review

Deutsche Bank sold out of Avenue Therapeutics, Inc. Common Stock (ATXI) in Q2 2021, closing a stake of 4 shares — an estimated $26K sold.

Deutsche Bank first reported a position in ATXI in Q1 2019 and held it in 7 quarters. The position peaked at $51K in Q1 2019. 24 funds tracked by Wall St. Rank hold ATXI as of Q2 2021.

  • Deutsche Bank reported no remaining Avenue Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Deutsche Bank sold 4 Avenue Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $26K.
  • Deutsche Bank first reported a position in Avenue Therapeutics, Inc. Common Stock in Q1 2019 and held it in 7 quarters.
  • Deutsche Bank's Avenue Therapeutics, Inc. Common Stock position peaked at $51K in Q1 2019.
  • 24 funds tracked by Wall St. Rank held Avenue Therapeutics, Inc. Common Stock as of Q2 2021.

Based on Deutsche Bank's 13F filing for Q2 2021, filed 11 Aug 2021.